Search results for "dilation"

showing 10 items of 304 documents

Restoration of perivascular adipose tissue function in diet-induced obese mice without changing bodyweight

2017

Background and Purpose We have recently shown that a reduced function of endothelial nitric oxide synthase (eNOS) in the perivascular adipose tissue (PVAT) contributes crucially to obesity-induced vascular dysfunction in mice. The current study was conducted to test the hypothesis that vascular dysfunction in obesity can be reversed by in vivo improvement of PVAT eNOS activity. Experimental Approach Male C57BL/6 J mice were fed a high-fat diet (HFD) for 22 weeks to induce obesity. During the last 4 weeks of HFD feeding, the obese mice were treated orally with the standardized Crataegus extract WS® 1442 which has been shown previously to improve eNOS activity. Key Results Diet-induced obesit…

0301 basic medicinePharmacologymedicine.medical_specialtyAortaEndotheliumAdipose tissueVasodilation030204 cardiovascular system & hematologyBiologybiology.organism_classification03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureEndocrinologyEnosInternal medicinemedicine.arterymedicineThoracic aortaDiet-induced obeseMyographBritish Journal of Pharmacology
researchProduct

2021

Angiotensin II (Ang II) has been implicated in the pathophysiology of various age-dependent ocular diseases. The purpose of this study was to test the hypothesis that Ang II induces endothelial dysfunction in mouse ophthalmic arteries and to identify the underlying mechanisms. Ophthalmic arteries were exposed to Ang II in vivo and in vitro to determine vascular function by video microscopy. Moreover, the formation of reactive oxygen species (ROS) was quantified and the expression of prooxidant redox genes and proteins was determined. The endothelium-dependent artery responses were blunted after both in vivo and in vitro exposure to Ang II. The Ang II type 1 receptor (AT1R) blocker, candesar…

0301 basic medicinePhysiologyClinical BiochemistryVideo microscopyVasodilation030204 cardiovascular system & hematologyPharmacologymedicine.disease_causeBiochemistry03 medical and health sciences0302 clinical medicinemedicineEndothelial dysfunctionMolecular BiologyAngiotensin II receptor type 1biologyChemistryCell Biologymedicine.diseaseAngiotensin IINitric oxide synthaseCandesartan030104 developmental biologycardiovascular systembiology.proteinhormones hormone substitutes and hormone antagonistsOxidative stressmedicine.drugAntioxidants
researchProduct

Inorganic nitrite and nitrate in cardiovascular therapy: A better alternative to organic nitrates as nitric oxide donors?

2017

In 1867 the organic nitrite, amyl nitrite, was introduced as a therapeutic agent in the treatment of angina pectoris and was later substituted by the organic nitrate nitroglycerin (NTG). Despite having a highly potent vasodilator capacity in veins>coronary arteries>arterioles, the vasodilator effects NTG are rapidly attenuated by the development of nitrate tolerance. We and others established that NTG treatment stimulates the production of reactive oxygen species such as superoxide and peroxynitrite with subsequent marked attenuation of the NTG vasodilator potency. The nitrite anion (NO2-) has more recently been characterized to possess novel pharmacotherapeutic actions such as modulation o…

0301 basic medicinePhysiologyVasodilator AgentsVasodilation030204 cardiovascular system & hematologyPharmacologyNitric OxideCardiovascular SystemNitric oxideAngina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNitratemedicineAnimalsHumansNitric Oxide DonorsNitriteNitritesPharmacologyNitratesSuperoxidemedicine.diseaseVasodilation030104 developmental biologychemistryBiochemistryCardiovascular DiseasesMolecular MedicineAmyl nitritePeroxynitriteSignal Transductionmedicine.drugVascular Pharmacology
researchProduct

JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study

2018

BackgroundPulmonary hypertension (PH) is a common disorder in patients with idiopathic pulmonary fibrosis (IPF) and portends a poor prognosis. Recent studies using vasodilators approved for PH have failed in improving IPF mainly due to ventilation (V)/perfusion (Q) mismatching and oxygen desaturation. Janus kinase type 2 (JAK2) is a non-receptor tyrosine kinase activated by a broad spectrum of profibrotic and vasoactive mediators, but its role in PH associated to PH is unknown.ObjectiveThe study of JAK2 as potential target to treat PH in IPF.Methods and resultsJAK2 expression was increased in pulmonary arteries (PAs) from IPF (n=10; 1.93-fold; P=0.0011) and IPF+PH (n=9; 2.65-fold; P<0.00…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyHypertension PulmonaryBlotting WesternMyocytes Smooth MuscleFluorescent Antibody TechniqueVasodilationVascular RemodelingReal-Time Polymerase Chain ReactionVascular remodelling in the embryo03 medical and health sciencesIdiopathic pulmonary fibrosisTransforming Growth Factor betaRight ventricular hypertrophyInternal medicinepulmonary hypertensionAnimalsHumansMedicineRNA Small InterferingRats WistarCells CulturedCell ProliferationBKCaJanus kinase 2biologybusiness.industryEndothelial CellsJanus Kinase 2idiopathic pulmonary fibrosismedicine.diseaseImmunohistochemistryPulmonary hypertensionIdiopathic Pulmonary FibrosisTriterpenesRatsPhenotype030104 developmental biologyJAK2biology.proteinCardiologyAnimal studiesJanus kinasebusinessSignal TransductionPulmonary artery smooth muscle cells Pulmonary artery endothelial cells.Thorax
researchProduct

Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin.

2016

Calcitonin gene related peptide (CGRP) and substance P (SP) are neuropeptides that are simultaneously released from nociceptive C-fibers. CGRP is a potent vasodilator, inducing a long-lasting increase in superficial skin blood flow, whereas SP induces only a brief vasodilation but a significant plasma extravasation. CGRP and SP may play important roles in the pathophysiology of various pain states but little is known about their interaction. Different concentrations of SP (ranging from 10-5M to 10-9M) were applied to the volar forearm of 24 healthy subjects via dermal microdialysis. SP was applied either alone or in combination with CGRP10-9M and CGRP 10-6M. As expected, SP induced a transi…

0301 basic medicinemedicine.medical_specialtyMicrodialysisCalcitonin Gene-Related PeptideVasodilationSubstance PCalcitonin gene-related peptideSubstance P03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundYoung Adult0302 clinical medicineEndocrinologyInternal medicinemedicineHumansNeprilysinSkinReceptor activity-modifying proteinintegumentary systemDose-Response Relationship DrugEndocrine and Autonomic SystemsChemistryGeneral MedicineCALCRLExtravasationVasodilationForearm030104 developmental biologyEndocrinologyNeurologyRegional Blood Flow030217 neurology & neurosurgeryNeuropeptides
researchProduct

The TRPA1 Channel in the Cardiovascular System: Promising Features and Challenges.

2019

The transient receptor potential ankyrin 1 (TRPA1) channel is a calcium-permeable nonselective cation channel in the plasma membrane that belongs to the transient receptor potential (TRP) channel superfamily. Recent studies have suggested that the TRPA1 channel plays an essential role in the development and progression of several cardiovascular conditions, such as atherosclerosis, heart failure, myocardial ischemia–reperfusion injury, myocardial fibrosis, arrhythmia, vasodilation, and hypertension. Activation of the TRPA1 channel has a protective effect against the development of atherosclerosis. Furthermore, TRPA1 channel activation elicits peripheral vasodilation and induces a biphasic bl…

0301 basic medicinemedicine.medical_specialtyhypertensionheart failureVasodilationReviewTRPA1 Channelarrhythmia03 medical and health sciencesTransient receptor potential channel0302 clinical medicineInternal medicinemedicineTRPA1 channelAnkyrinPharmacology (medical)vasodilationchemistry.chemical_classificationPharmacologybusiness.industrylcsh:RM1-950food and beveragesmedicine.diseaseBlockademyocardial ischemia–reperfusion injurylcsh:Therapeutics. Pharmacology030104 developmental biologyBlood pressurechemistry030220 oncology & carcinogenesisHeart failureCardiologyMyocardial fibrosismyocardial fibrosisatherosclerosisbusinesspsychological phenomena and processesFrontiers in pharmacology
researchProduct

NO donors. Part 16: investigations on structure-activity relationships of organic mononitrates reveal 2-nitrooxyethylammoniumnitrate as a high potent…

2007

The vasoactive properties of 14 organic mononitrates were investigated in vitro using PGF(2alpha)-precontracted porcine pulmonary arteries. A surprisingly wide range of vasorelaxant potencies was observed (pD(2): 3.36-7.50). Activities showed to be highly sensitive to the molecular structure and the substituents at the molecular carrier of the nitrate group. A correlation between lipophilicity and vasorelaxant potency could not be recognized. 2-Nitrooxyethylammoniumnitrate (1) was found to be slightly superior to the high potency trinitrate GTN.

2-nitrooxyethylammoniumnitrateNitratesChemistryStereochemistryVasodilator AgentsOrganic ChemistryClinical BiochemistryPharmaceutical ScienceVasodilationBiochemistryChemical synthesisIn vitroNo donorsQuaternary Ammonium CompoundsStructure-Activity RelationshipDrug DiscoveryLipophilicityMolecular MedicinePotencyStructure–activity relationshipNitric Oxide DonorsMolecular BiologyBioorganicmedicinal chemistry letters
researchProduct

Hilbert space operators with two-isometric dilations

2021

A bounded linear Hilbert space operator $S$ is said to be a $2$-isometry if the operator $S$ and its adjoint $S^*$ satisfy the relation $S^{*2}S^{2} - 2 S^{*}S + I = 0$. In this paper, we study Hilbert space operators having liftings or dilations to $2$-isometries. The adjoint of an operator which admits such liftings is characterized as the restriction of a backward shift on a Hilbert space of vector-valued analytic functions. These results are applied to concave operators (i.e., operators $S$ such that $S^{*2}S^{2} - 2 S^{*}S + I \le 0$) and to operators similar to contractions or isometries. Two types of liftings to $2$-isometries, as well as the extensions induced by them, are construct…

47[MATH.MATH-FA]Mathematics [math]/Functional Analysis [math.FA]A-contractionFunctional Analysis (math.FA)Mathematics - Functional AnalysisMathematics - Spectral Theory47A63Dirichlet shift MSC (2010): 47A0547A20FOS: Mathematicsdilationsconcave operator2-isometric lifting47A15Spectral Theory (math.SP)
researchProduct

Gastric Dilation due to a Neuroleptic Agent in an Elderly Patient: A Case Report

2014

Neuroleptics may cause side effects, some of which are little known. We describe here a case of gastric dilation related to treatment with a neuroleptic in an elderly man. To our knowledge, such a case has never been reported in the literature. A 76-year-old man, living in a nursing home, was hospitalized for general weakness and abdominal pain. He had dementia with behavioral disorders treated with cyamemazine, a sedative and anxiolytic neuroleptic. Given a clinical suspicion of intestinal occlusion, an abdominopelvic computerized tomography scan was performed before the patient was admitted to our hospital. This computerized tomography scan did not show intestinal occlusion and there was …

Abdominal painWeaknessmedicine.medical_specialtyGastric Dilationmedicine.drug_classbusiness.industrylcsh:Rlcsh:MedicineCase ReportGeneral Medicinemedicine.diseaseCyamemazineSurgerychemistry.chemical_compoundchemistrySedativeAnesthesiamedicineDementiamedicine.symptomMedical prescriptionbusinessElderly patientCase Reports in Medicine
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct